Icon

RYZUMVI (NDA217064)- (EQ 0.75% BASE)

PHENTOLAMINE MESYLATE FAMYGEN LIFE SCI
EQ 0.75% BASE
No Yes
2039-Oct-25 Expired
None 2026-Sep-25
None No
Ryzumvi is an alpha adrenergic blocker indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
0 0 0
Total Other Developers 1
Drugs with Suitability No
EQ 0.75% BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.